Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pCCLCHIM-p47 in p47 AR-CGD
NCT06253507Phase 2Enrolling by invitation
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2024
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47 in chronic granulomatous disease (CGD), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Engraftment of genetically modified cells at 6 months. Started Jun 2024; status: enrolling by invitation.
02
Drugs
Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on NCT06253507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253507.